AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie Inc. (ABBV) Stock Price & Market Analysis
ABBV · NYSE · Biotechnology
$285.64
▲ +$0.4500(+0.16%)4:01 PM ET - vs previous closeQuote as of Oct 23, 2026, 4:01 PM EDT
Regular-session close · Oct 23, 2026, 4:01 PM EDT.
Long-term rangesAvailable historyHide
Historical range: 2013-01-02–2026-10-23. Earlier trading may not be included.
Loading price chart…
Data dates
PriceAt closeLast traded
FundamentalsLast checked
AnalystLast checked
NewsLatest item
What matters next
Next important events
- Oct 30, 2026Next earnings · Before market openConfirmed · Before market open · Last verified 2026-10-25
Countdown
6 days out
Reported fundamentals
ABBV financial overview
Annual revenue
USD 61.16B
Sales for the fiscal year ended Dec 31, 2025. This is not trailing twelve-month revenue.
Revenue change
+8.6%
Change versus the fiscal year ended Dec 31, 2024.
Net profit margin
6.9%
Net income divided by revenue for the fiscal year ended Dec 31, 2025. This is not the trailing margin.
These reported results describe the business’s recent scale and profitability. Compare cash generation and valuation before forming an investment view; historical growth is not a forecast.
Company · ProfileAbout AbbVie Inc. (ABBV)Sector, leadership, and how AbbVie Inc. earns its revenue.Healthcare
AbbVie Inc.
NYSE · ABBV · US
Company overview as of Oct 25, 2026.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- North Chicago, IL, United States
- Country
- US
- Founded
- 2013
- Employees
- 57,000
- CEO
- Mr. Robert A. Michael CPA
- Exchange
- NYSE
Business model & operating evidenceExplore business exposure, reported operating measures and the evidence behind growth and profitability claims.
AI business exposure
- Revenue exposure
- AI-specific revenue is not separated in the available company statements.
- Capital-spending dependency
- No reviewed quantitative dependency model is available.
- Compute role
- See the sourced business description; AI labels do not establish compute revenue.
- Platform examples
- An exhaustive, consistently defined product inventory is unavailable.
- Ecosystem links
- Supplier and customer links require reviewed disclosures.
Narrative versus numbers
Demand is expanding
Supporting observation: 10.2%
Year-over-year growth in the latest quarter. This differs from the fiscal-year revenue change shown above. · 2026-06-30
Growth produces accounting profit
Supporting observation: 9.8%
Reported-period net margin. A positive figure supports accounting profitability, not cash generation. · 2026-10-24T19:02:09.563Z
The business generates cash after investment
Supporting observation: USD 3.11B
Latest reported free cash flow. It is not a forecast and may cover a different period from the fiscal-year figures above. · 2026-06-30
These are explicit tests of individual claims, not an overall bull/bear rating. Demand growth can coexist with valuation, concentration and financing risk.
Operating measures
- Revenue
- $16.99Bquarter ended Jun 30, 2026
- Operating margin
- 37.9%quarter ended Jun 30, 2026
- EPS
- $2.03quarter ended Jun 30, 2026
- Capital expenditure
- $322.00Mquarter ended Jun 30, 2026
- Free cash flow
- $3.11Bquarter ended Jun 30, 2026
- Free cash flow margin
- 18.3%quarter ended Jun 30, 2026
- Operating cash / net income
- 0.95×quarter ended Jun 30, 2026
- Revenue growth year over year
- 10.2%quarter ended Jun 30, 2026
Competitors & comparisonsCompare industry peers, reporting periods and related funds. Business mix and valuation bases may differ.
Reviewed company relationships
Direct competitors, industry comparables and thematic alternatives have different uses. Compare fiscal periods and business mix before comparing multiples.
Company-specific relationship evidence is not included in this snapshot. Explore the industry comparisons below without assuming that every comparable is a direct competitor.
A disclosed relationship is historical evidence, not a current valuation or a recommendation.
Valuation & fund comparisonsExplore dated peer valuations, growth comparisons and related funds.
Governance & sustainability
Market closed
Regular hours: 9:30 AM–4:00 PM America/New_York
Next open: 2026-10-26 · 9:30 AM America/New_York
Exchange calendar includes scheduled holidays and early closes. Extended-session prices appear separately only when supplied by the quote source.
Shortcuts
With research tools focused: / search · W watchlist · C compare · F financials · E earnings · N news · T technicals · Esc close
TECHi.com